MicroRNA-181b expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3

He, Li; Yao, Hua; Fan, Lingling; Liu, L; Qiu, Shuang; Li, X; Gao, Jin; Hao, Chunbo

doi:10.4238/2013.april.2.17

Cited by 21 publications

(19 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Fig 3C, downstream targeted genes of STAT3 such as CYCLIN D1 , SURVIVIN , and BCL-XL in RH30, RD, and RH28 rhabdomyosarcoma cell lines were down-regulated when treated with Bazedoxifene. In addition, two STAT3 activation dependent microRNA-21(miR-21) and microRNA-181b (miR-181b), which were recently recognized oncogene implicated in multiple malignancy-related processes such as cell proliferation, anti-apoptosis, metastasis, and drug resistance [39, 40], were examined in RH30 and RH28 cells treated with Bazedoxifene using quantitative RT-PCR as described in Material and Method. We observed both miR-21 and miR-181b gene expression were dramatically reduced in RH30 and RH28 rhabdomyosarcoma cell lines by Bazedoxifene treatment (Fig 3D), which was consistent with the report that miR-21 expression was strongly suppressed by silence of STAT3 siRNA [41].…”

Section: Resultsmentioning

confidence: 99%

Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

Bid

Chen

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

Interleukins-6 (IL-6)/GP130 signaling pathway represents a promising target for cancer therapy due to its critical role in survival and progression of multiple types of cancer. We have identified Bazedoxifene, a Food and Drug Administration (FDA)-approved drug used for the prevention of postmenopausal osteoporosis, with novel function as inhibitor of IL-6/GP130 interaction. In this study, we investigate the effect of Bazedoxifene in rhabdomyosarcoma and evaluate whether inhibiting IL-6/GP130 signaling is an effective therapeutic strategy for rhabdomyosarcoma. The inhibitory effect of Bazedoxifene was assessed in rhabdomyosarcoma cell lines in vitro and RH30 xenograft model was used to further examine the suppressive efficacy of Bazedoxifene on tumor growth in vivo. Rhabdomyosarcoma cells showed their sensitivity to GP130 inhibition using gene knockdown or neutralized antibody, suggesting IL-6/GP130 as therapeutic target in rhabdomyosarcoma cells. Bazedoxifene decreased the signal transducer and activator of transcription3 (STAT3) phosphorylation, blocked STAT3 DNA binding, and down-regulated the expression of STAT3 downstream genes. Bazedoxifene also induced cell apoptosis, reduced cell viability, and inhibited colony formation in rhabdomyosarcoma cells. The inhibition of colony formation, STAT3 phosphorylation, or cell viability following Bazedoxifene treatment was partially reversed by addition of excess IL-6 or overexpression of constitutive STAT3, respectively, supporting Bazedoxifene acted through IL-6/GP130 signaling. In addition, Bazedoxifene repressed cell invasion and angiogenesis in vitro. Furthermore, oral administration of Bazedoxifene significantly suppressed tumor growth and expression of STAT3 phosphorylation in nude mice bearing established human rhabdomyosarcoma xenograft. Taken together, these findings validate IL-6/GP130 signaling as therapeutic target in rhabdomyosarcoma and provide first evidence that Bazedoxifene may serve as a novel promising drug targeting IL-6/GP130 for treatment of rhabdomyosarcoma.

show abstract

Section: Resultsmentioning

confidence: 99%

Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

Bid

Chen

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…In addition, it has been illuminated that miR‐181b might suppress breast cancer cells’ capacity of metastasis by targeting CXCL1 and CXCL2, a couple of inflammatory cytokines 42, 43, 44. He et al45 arrived at conclusions that miR‐181b was highly expressed with prostate cancer tissues and cell line (ie. PC‐3), and transfecting miR‐181b anti‐sense nucleotide sequences into PC‐3 cell line could result in increased cell apoptosis, decreased cell proliferation and inhibited cell invasion.…”

Section: Discussionmentioning

confidence: 99%

The interplay of LncRNA ANRIL and miR‐181b on the inflammation‐relevant coronary artery disease through mediating NF‐κB signalling pathway

Guo

Tang

et al. 2018

J Cellular Molecular Medi

104

View full text Add to dashboard Cite

This study was designed to investigate whether ANRIL affected the aetiology of coronary artery disease (CAD) by acting on downstream miR‐181b and NF‐κB signalling. Altogether 327 CAD patients diagnosed by angiography were included, and mice models of CAD were established. Human coronary endothelial cells (HCAECs) and human umbilical vein endothelial cells (HUVECs) were also purchased. In addition, shRNA‐ANRIL, shRNA‐NC, pcDNA3.1‐ANRIL, miR‐181b mimic, miR‐181b inhibitor and miR‐NC were transfected into the cells. The lipopolysaccharides (LPS) and pyrrolidine dithiocarbamate (PDTC) were also added to activate or deactivate NF‐κB signalling. Both highly expressed ANRIL and lowly expressed miR‐181b were associated with CAD population aged over 60 years old, with smoking history, with hypertension and hyperlipidemia, with CHOL H 4.34 mmol/L, TG ≥ 1.93 mmol/L and Hcy ≥ 16.8 μmol/L (all P < 0.05). Besides, IL‐6, IL‐8, NF‐κB, TNF‐α, iNOS, ICAM‐1, VCAM‐1 and COX‐2 expressions observed within AD mice models were all beyond those within NC and sham‐operated groups (P < 0.05). Also VEGF and HSP 70 were highly expressed within AD mice models than within NC and sham‐operated mice (P < 0.05). Transfection of either pcDNA‐ANRIL or miR‐181b inhibitor could significantly fortify HCAECs’ viability and put on their survival rate. At the meantime, the inflammatory factors and vascular‐protective parameters were released to a greater level (P < 0.05). Finally, highly expressed ANRIL also notably bring down miR‐181b expression and raise p50/p65 expressions within HCAECs (P < 0.05). The joint role of ANRIL, miR‐181b and NF‐κB signalling could aid in further treating and diagnosing CAD.

show abstract

“…Upregulation of "hsa-miR199a" and "hsa-miR-943" [7,19] and downregulation of "hsa-miR-127-3p" [36] are found responsible for melanoma. The investigations by Feng et al [6] and He et al [9] reported that upregulation of "hsa-miR-505" and "hsa-mir181b," respectively, causes prostate cancer by promoting cell proliferation in prostate gland, and our miRNA selection methodology also identified them as the relevant ones. FMIMS also predicted some miRNAs which target cancer-related genes.…”

Section: Discussionmentioning

confidence: 89%

Identifying relevant group of miRNAs in cancer using fuzzy mutual information

Pal

Ray

Pal

2015

Med Biol Eng Comput

View full text Add to dashboard Cite

MicroRNAs (miRNAs) act as a major biomarker of cancer. All miRNAs in human body are not equally important for cancer identification. We propose a methodology, called FMIMS, which automatically selects the most relevant miRNAs for a particular type of cancer. In FMIMS, miRNAs are initially grouped by using a SVM-based algorithm; then the group with highest relevance is determined and the miRNAs in that group are finally ranked for selection according to their redundancy. Fuzzy mutual information is used in computing the relevance of a group and the redundancy of miRNAs within it. Superiority of the most relevant group to all others, in deciding normal or cancer, is demonstrated on breast, renal, colorectal, lung, melanoma and prostate data. The merit of FMIMS as compared to several existing methods is established. While 12 out of 15 selected miRNAs by FMIMS corroborate with those of biological investigations, three of them viz., "hsa-miR-519," "hsa-miR-431" and "hsa-miR-320c" are possible novel predictions for renal cancer, lung cancer and melanoma, respectively. The selected miRNAs are found to be involved in disease-specific pathways by targeting various genes. The method is also able to detect the responsible miRNAs even at the primary stage of cancer. The related code is available at http://www.jayanta.droppages.com/FMIMS.html .

show abstract

MicroRNA-181b expression in prostate cancer tissues and its influence on the biological behavior of the prostate cancer cell line PC-3

Cited by 21 publications

References 20 publications

Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy

The interplay of LncRNA ANRIL and miR‐181b on the inflammation‐relevant coronary artery disease through mediating NF‐κB signalling pathway

Identifying relevant group of miRNAs in cancer using fuzzy mutual information

Contact Info

Product

Resources

About